Uncategorized
calendar_month Nov 17, 2026

Rhythm Pharmaceuticals Says Rare Obesity Drug Delivers Sustained Two-Year BMI Reductions

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) on Monday presented two-year Phase 3 setmelanotide results and global diagnostic criteria at ObesityWeek 2026, highlighting sustained weight reductions and earlier diagnosis for acquired hypothalamic obesity (HO).

The biopharmaceutical company and its collaborators shared four posters and one oral presentation.

Hypothalamic obesity is a rare, severe form of obesity caused by damage to the hypothalamus—the part of the brain at the base of the skull that regulates appetite, metabolism, body temperature, and hormone production.

Unlike common obesity, it stems from a physical disruption of the brain’s energy-balance center.

The MC4R pathway is responsible for controlling physiological functions such as energy expenditure, hunger, and weight regulation.

Two-Year Setmelanotide Phase 3 Trial Results

Dr. Susan Phillips, a pediatric endocrinologist at the University of California San Diego/Rady Children’s Hospital, presented two-year results from the Phase 3 TRANSCEND trial’s open-label extension.

Among 125 patients entering the extension, 81 completed two years of treatment at analysis, including 54 continuous setmelanotide recipients and 27 who switched from placebo after one year.

Continuous setmelanotide patients achieved a -18.8% mean BMI change at two years, while patients switching from placebo posted a -16.5% mean BMI change.

Adults saw mean BMI reductions of 21.2% and 21.0%, respectively, and pediatric patients recorded mean BMI z-score declines of -1.71 and -1.49.

Setmelanotide showed a safety profile consistent with earlier acquired HO trials.

Rhythm also presented three posters covering TRANSCEND patient outcomes, weight category improvements, and final Phase 3 results.

In March, the U.S. Food and Drug Administration (FDA) approved an expanded indication for Imcivree (setmelanotide) to treat acquired hypothalamic obesity.

The FDA also approved setmelanotide in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome or Pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency.

RYTM Price Action: Rhythm Pharmaceuticals shares were down 0.94% at $106.47 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo by shisu_ka via Shutterstock